Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 5/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 6/20 | 0.34 |
| ▸ | ATP4A | P20648 | 5/20 | 0.33 |
| ▸ | ATP4B | P51164 | 5/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.32 |
| ▸ | HTR3B | O95264 | 2/20 | 0.32 |
| ▸ | HTR3A | P46098 | 2/20 | 0.32 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.32 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.32 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6142194 | 0.81 | ADRA2A (0.54) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL8581269 | 0.77 | APLNR (0.34) | — | |
| SCHEMBL5544044 | 0.72 | ALDH1A1 (0.33) | NPC1RAB9A | |
| SCHEMBL8580366 | 0.72 | CYP3A4 (0.34) | — | |
| SCHEMBL7458773 | 0.71 | ALDH1A1 (0.35) | MAPTNPC1RAB9ANPSR1 | |
| SCHEMBL21741609 | 0.70 | NPC1 (0.33) | NPC1RAB9A | |
| SCHEMBL7206716 | 0.69 | NPC1 (0.33) | NPC1RAB9A | |
| SCHEMBL6129371 | 0.68 | MAPT (0.41) | MAPTNPC1RAB9A | |
| SCHEMBL5544035 | 0.68 | ALDH1A1 (0.33) | NPC1RAB9ANPSR1 | |
| SCHEMBL30002773 | 0.68 | MAPT (0.41) | MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610720-B2 | Administering to the patient an alpha-2 adrenoreceptor agonist for the treatment or prevention of emesis | MERCK FROSST CANADA & CO. (CA) | 2003-08-26 | — | — | US | disclosed |
| US-20020045565-A1 | Method for treating or preventing emesis | MERCK FROSST CANADA LTD. (CA) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045565-A1 | Method for treating or preventing emesis | ADRB2, ADRA2A, ADRA2C | ADRA2A 2/4885ADRA2B 4/4885ADRA2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.